JP2010069270A - Device for administration of functional medicine and method and apparatus for manufacturing the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To solve the problem that conventionally, in the administration of a tonic or a medicinal medicine by an intravenous drip, a skin injury is likely to occur since an injection needle is used, especially when the intravenous drip is repeatedly performed, a skin injury section spreads too much and puts excessive corporal and mental burdens on a patient, and the development of a new means and a new method for the administration of the tonic, etc. which can replace the intravenous drip, is an important problem, and moreover, in the case of applying the technique of a conventional fine carbohydrate needle as the administration means of those, etc., and the way for embodying is a very important subject. <P>SOLUTION: In the device for administration of functional medicine, since maltose or carbohydrate containing the tonic and a medicinal medicine is used as the principal component of the carbohydrate of the fine carbohydrate needle and furthermore the fine carbohydrate needle is in a minute form, the carbohydrate of the fine carbohydrate needle, which remains on the inside of the skin, dissolves and becomes the tonic and the transdermal administration of the tonic, etc. can be simply and continuously carried out in the state of analgesia, and moreover, because of a manufacturing method which produces the fine carbohydrate needle on a mount in predetermined conditions, an effect capable of manufacturing it with high accuracy, at a low cost, and in a simple way is provided. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a functional agent administration device for the purpose of transdermally administering a nutrient or a pharmaceutical agent to the human body, a method for producing the device, and a production apparatus. The present invention also provides a fine needle mainly composed of a saccharide, which is a main part of the functional agent administration device, that is, the fine saccharide needle itself has a function as a nutrient, and the nutrition of the nutrient by the fine saccharide needle. It relates to the skin administration technology. Furthermore, the present invention relates to a transdermal administration technique of a pharmaceutical agent that is administered to a human body by containing the pharmaceutical agent in the carbohydrate of the fine sugar needle.

  Conventionally, a safe representative means of administration of nutrients and pharmaceutical agents to the human body has been infusion of infused nutrients and pharmaceutical agents performed by a person lying on a bed. However, in the event of a disaster or accident, or during fatigue due to excessive sports, even if there is no infusion device etc. on site, it is necessary to promptly administer nutrients and pharmaceuticals as an emergency measure. It is reported greatly in.

  Against the background of such social needs, in recent years, the manufacturing technology of fine sugar needles has progressed, and with the development in application, it is a new attempt. It was questioned whether it could be applied. However, since there is a limit to the amount of fine sugar needles that can administer nutrients and the like, there has been a demand for a device that can secure the necessary dose of nutrients and the like. The securing of this dose can be solved by providing a plurality of fine needles, but in that case, it is important to develop a technology that enables cost reduction by mass production.

In the development of mass production technology for such fine sugar needles, in the manufacture of skin needles made of biodegradable substances (with maltose as the main ingredient) using a conventional stretching method, the heat-melted main ingredient is finely divided. After extruding from a simple nozzle, and attaching the extruded fine main component material part to a substrate (paper, tape, plastic or metal sheet, etc.), the part is stretched to make a needle for each skin individually. A method and apparatus (see, for example, Patent Document 1) are provided.
Republished patent (A1) JP WO2006 / 077742

  Generally, oral administration is the main means of supplementing nutrients, etc., but when oral administration is difficult, nutrients are administered by intravenous infusion, but intravenous infusion is performed using a syringe needle. If the skin surface is damaged by a needle wound, and repeated administration of nutrients by instillation is repeated many times, the damaged part of the skin surface will spread too much, putting an excessive physical and mental burden on the patient. In addition, it was extremely difficult to continue the infusion itself, which was a big problem with infusion. Therefore, in order to overcome such drip problems, the development of new means and methods that can replace drip has become an issue, and it is particularly urgent how to apply the technology of conventional fine sugar needles. It was also an issue.

  In the case where many conventional fine sugar needles are erected on a substrate, as described in Patent Document 1 above, the substrate is sticky and has heat resistance and stretchability, Since tape, plastic or metal sheets were used, the adhesion strength of the fine sugar needle to the substrate was not sufficient, which made it easy for the fine sugar needle to come off the substrate, or when inserting the skin The product yield tends to be sluggish, and the development of means for solving this problem has been an issue.

  Also, conventionally, since a saccharide fine needle is directly provided on a substrate, the saccharide material heated and melted from the nozzle is extruded from the nozzle, the extruded fine saccharide material portion is adhered to the substrate, and the nozzle is gradually moved from the substrate. The fine sugar needles were erected on the substrate by pulling them apart, that is, by extending the sugar material part, but the fine nozzle that pushes the heated and melted sugar material needs to be processed with great precision, so computer control Including the nozzle processing by the nozzle, the extrusion amount control from the nozzle, and the movement control of the nozzle, it becomes an expensive manufacturing apparatus, which causes a high cost. In addition, since the same number of nozzles are required to stand a plurality of fine saccharide needles on the substrate, it is a factor that further increases the cost. Furthermore, among the plurality of nozzles, the variation between the nozzles that appears due to the difference between the individual nozzles became the variation of the fine sugar needles, which became an obstacle to mass production or homogenization. Therefore, the development of means for solving these problems has been an issue.

  Furthermore, when taking a structure that increases the number of conventional fine sugar needles to secure the transdermal dosage of nutrients, etc., the same number of nozzles is required, but due to the limit of miniaturization of the nozzle outer shape. In order to secure the nozzle area, there is a limit to the number density (integration degree) of fine sugar needles per unit area on the substrate, which is also a problem to be solved.

  In addition, when a large number of conventional fine sugar needles are provided on a substrate, in order to reduce costs, a single needle is used to provide a fine needle while moving to the position where each needle is provided, thereby forming a large number of sugar needles. Although there is a method, the addition of the moving mechanism and the moving time are increased, and the production efficiency is limited. The high cost is not negligible, and the development of a means for solving this problem has been an issue.

  Next, in the conventional stretching method using a nozzle, it is necessary to provide heating heaters at two locations, the nozzle portion and the substrate placement portion, and two temperature control mechanisms for the device scale are required. Also, the cost was disadvantageous. Further, when a plurality of nozzles are provided, the number of temperature control mechanisms is required, which leads to higher costs, and the development of means for solving these problems has become an important issue.

In order to solve the various problems described above, the present inventors have conducted extensive research and development.In the present invention, as means and methods for solving these problems,
(1) A pedestal made of a substantially cylindrical polysaccharide having a pedestal height of 10 μm to 2 mm, a pedestal top surface diameter of 30 μm to 1 mm, and a pedestal bottom surface diameter of 40 μm to 1.5 mm on the substrate made of polysaccharide. On the pedestal, a substantially conical or bell-shaped fine sugar having a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface diameter of 30 μm to 1 mm in contact with the pedestal top surface A functional agent administration device characterized by having a structure provided with a needle, and
(2) A pedestal made of a substantially cylindrical polysaccharide having a pedestal height of 10 μm to 2 mm, a pedestal top surface diameter of 30 μm to 1 mm, and a pedestal bottom surface diameter of 40 μm to 1.5 mm on the substrate made of polysaccharide. And a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, a needle bottom surface diameter of 30 μm to 1 mm in contact with the top surface of the needle, and a maximum at the middle part in the needle length direction. A functional agent administration device characterized by having a structure provided with a jewel-shaped fine sugar needle having a diameter of 50 μm to 1.5 mm, and
(3) On a substrate made of polysaccharide, a pedestal height of 10 μm to 2 mm, a pedestal top surface is inscribed or circumscribed in a circle with a diameter of 30 μm to 1 mm, and a pedestal bottom surface in contact with the substrate is a circle with a diameter of 40 μm to 1.5 mm A plurality of pedestals made of a substantially polygonal-pillar-shaped polysaccharide that is inscribed or circumscribed are provided. On the pedestal, a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface are the same as the top surface of the pedestal A functional agent administration device, characterized in that it is a structure provided with a fine saccharide needle having a substantially polygonal pyramid shape or a substantially bell-shaped shape, and
(4) On a substrate made of polysaccharide, a pedestal height of 10 μm to 2 mm, a pedestal top surface is inscribed or circumscribed in a circle with a diameter of 30 μm to 1 mm, and a pedestal bottom surface in contact with the substrate is a circle with a diameter of 40 μm to 1.5 mm A plurality of pedestals made of a substantially polygonal-pillar-shaped polysaccharide that is inscribed or circumscribed are provided. On the pedestal, a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface are the same as the top surface of the pedestal The shape is a structure in which an approximately pearl-shaped fine sugar needle having a substantially polygonal shape that is inscribed or circumscribed to a circle having a diameter of 50 μm to 1.5 mm is provided in a substantially middle portion in the needle length direction. Functional agent administration device, and
(5) The functional agent administration device according to any one of (1) to (4), wherein the polysaccharide is pullulan or carboxymethylcellulose, and the sugar of the fine sugar needle is maltose, and
(6) The polysaccharide as described above, wherein the polysaccharide is pullulan or carboxymethylcellulose, and the carbohydrate of the fine sugar needle is a carbohydrate mixture containing maltose as a main component and glucose or trehalose as another component. ) To (4) any one of the functional agent administration devices, and
(7) Carbohydrates of the fine sugar needles include vitamin A, vitamin B complex, vitamin C, vitamin D, vitamin E, vitamin K, glutamine, essential amino acid, non-essential amino acid, γ-aminobutyric acid, taurine, fatty acid A functional agent administration device according to (5) or (6) above, which contains one or more nutrients selected from nucleic acids, adrenaline, and
(8) To the sugar of the fine saccharide needle, analgesic agent, anti-inflammatory agent, antipyretic analgesic anti-inflammatory agent, antifungal agent, antibacterial agent, antiviral agent, cardiotonic agent, thrombolytic agent, hemostatic agent, diuretic agent, hypertension treatment 1 pharmaceutical agent selected from drugs, anesthetics, sedatives, sleeping pills, anticonvulsants, anti-anxiety drugs, sickness medicines, tranquilizers, antidepressants, sleep sedatives, antiprotozoal drugs The functional agent administration device according to (5) or (6) above, and
(9) After forming a plurality of pedestals made of the polysaccharide by mold molding on the substrate made of the polysaccharide, the pedestal is placed in a vertically downward direction on a stage having a lift control mechanism along a horizontal plane. By attaching the upper surface of the pedestal to the upper surface of the molten saccharide in the saccharide heating container whose temperature is controlled to 90 ° C. to 120 ° C. in a stationary state, and then raising and lowering the stage The method for producing a functional agent administration device according to any one of (1) to (8), wherein the fine sugar needle is molded on the pedestal upper surface, and
(10) After forming a plurality of pedestals made of the polysaccharide by die molding on the substrate made of the polysaccharide, the pedestal is placed in a vertically downward direction on a stage having a lifting control mechanism and along a horizontal plane. By attaching the upper surface of the pedestal to the upper surface of the molten saccharide in the saccharide heating container whose temperature is controlled to 90 ° C. to 120 ° C. in a stationary state, and then raising and lowering the stage The functional agent administration device according to any one of (1) to (8) according to the method for producing a functional agent administration device, wherein the fine sugar needle is formed on the pedestal upper surface, and
(11) The fine sugar needle is placed on the upper surface of the pedestal by a control method in which the up / down movement distance of the stage is minutely divided digitally, and the up / down movement distance is arbitrarily changed to finely adjust the movement speed of the stage up / down movement. Is produced with high accuracy, and the method for producing a functional agent administration device according to (9) above, and
(12) In the method for manufacturing a functional agent administration device according to (9), the moving distance of the stage is finely divided in a digital manner, and the moving speed of the moving of the stage is reduced by arbitrarily changing the moving distance. The functional agent administration device according to any one of (1) to (8) according to the method for producing a functional agent administration device, wherein the fine sugar needle is formed on the pedestal upper surface with high accuracy by an adjustment control method. As well as
(13) In the manufacturing apparatus of the functional agent administration device, the carbohydrate heating container having a temperature control mechanism of 90 ° C. to 120 ° C., and the elevation control capable of attaching the substrate so that the pedestal points in the vertically downward direction A stage along a horizontal plane having a mechanism, and further comprising the stage having an alignment control mechanism for arbitrarily positioning a distance between the upper surface of the pedestal and the upper surface of the molten saccharide. 1) to (8) a device for producing a functional agent administration device according to any one of
It is what.

  In the functional agent administration device of the present invention, when an emergency treatment by infusion is required, when the fine sugar needle of the present invention is inserted into the skin as a substitute for infusion, it is easily inserted into the skin, and the upper surface of the pedestal and The fine sugar needle easily breaks in the vicinity of the contact portion on the bottom surface of the needle and remains in the skin, and the fine sugar needle remaining in the skin itself becomes a nutrient or a pharmaceutical agent. Can be easily and painlessly administered to the affected area, and the physical and mental burden on the patient can be greatly reduced. Further, the fine sugar needle in the functional agent administration device of the present invention can be continuously used on the skin without damaging or deforming the skin because the sugar needle itself is minute. It has become possible. Furthermore, in the functional agent administration device of the present invention, other nutrients and pharmaceutical agents can be easily contained in the carbohydrate of the fine saccharide needle, thereby freeing the functionality of the functional agent administration device. The degree can be greatly improved.

  In the functional agent administration device of the present invention, without providing the fine sugar needles directly on the substrate, a plurality of pedestals made of polysaccharides are provided on the substrate made of polysaccharides, one on each pedestal. By providing a fine sugar needle, the high adhesion between the polysaccharide and sugar with high weldability, the adhesion of the fine sugar needle to the pedestal becomes strong, and the product yield of the fine sugar needle is increased. It became possible to improve. In addition, conventionally, the shape of the fine sugar needle is mainly a cone shape or a polygonal pyramid shape, and there has been a limit to the dosage of nutrients, pharmaceutical agents, etc., but in the present invention, a bell shape, a jewel shape, By adopting this general shape, it has become possible to greatly increase the dose of nutrients and the like.

  In the method for producing a functional agent administration device of the present invention, a plurality of pedestals made of the polysaccharide by molding are formed on the substrate made of the polysaccharide, and then a stage along the horizontal plane having an elevation control mechanism. The substrate is attached so that the pedestal points in a vertically downward direction, and the upper surface of the pedestal is brought into contact with the upper surface of the molten saccharide in a saccharide heating container whose temperature is controlled at 90 ° C. to 120 ° C. in a stationary state. After that, the fine sugar needle is formed on the pedestal upper surface by moving the stage up and down, so there is no need for the nozzle mechanism necessary for the conventional stretching method, and this can greatly reduce the cost. It became. In addition, since the fine pedestal provided on the substrate is molded by a mold, the variation between the pedestals can be suppressed to a sufficiently small degree of variation of the mold, and the fine saccharide needle by raising and lowering the stage once. As a result of this molding, a large number of fine sugar needles can be molded simultaneously in parallel, and the fine sugar needles can be made uniform and mass-produced. In the present invention, the bottom surface of the fine homogeneous needle has the same shape as the top surface of the pedestal. This is because the molten saccharide material welded to the top surface of the pedestal is stretched by raising and lowering the stage. This is caused by molding a sugar needle.

  The functional agent administration device of the present invention has a structure in which the number of fine sugar needles is increased in order to ensure the dosage of a nutritional agent or a pharmaceutical agent, but since a plurality of pedestals can be produced with high precision by a mold, the pedestal Can be molded by increasing the number density per unit area of the pedestal on the substrate surface by increasing the precision of the mold production, thereby increasing the number density of the fine sugar needles per unit area of the substrate It became possible to take the structure.

  In the method for producing a functional agent administration device of the present invention, since a method in which fine sugar needles are provided on a plurality of pedestals formed on a substrate is adopted, the sugar heating unit heats and melts the sugar. Therefore, since it can be accommodated in only one place, the structure of the apparatus can be simplified and the cost can be greatly reduced.

  When the functional agent administration device of the present invention is used for a patient as a substitute for infusion, that is, when a fine sugar needle is inserted into the patient's skin, the fine sugar needle remaining in the skin itself becomes a nutrient or a pharmaceutical agent, It was possible to easily administer nutrients and the like to the affected area in a painless state, and the physical and mental burden on the patient could be greatly reduced. In addition, the fine sugar needle in the functional agent administration device of the present invention has an effect that it can be continuously used on the skin without damaging or deforming the skin because the sugar needle itself is minute. Was also obtained. Furthermore, in the functional agent administration device of the present invention, other nutrients and pharmaceutical agents can be easily contained in the carbohydrate of the fine saccharide needle, thereby freeing the functionality of the functional agent administration device. The effect that the degree can be greatly increased was also obtained.

  By providing a plurality of pedestals made of polysaccharides on a substrate made of polysaccharides by using the functional agent administration device of the present invention, and providing a fine saccharide needle one by one on each pedestal, a polysaccharide having high weldability and Due to the high adhesion to sugar, the adhesion of the fine sugar needle to the pedestal became strong, and the effect of improving the product yield of the fine sugar needle was obtained. Moreover, in this invention, the effect that the dosage of nutrients etc. can be increased dramatically was also acquired by adopting a bell shape, a jewel shape, and those approximate shapes.

  In the method for producing a functional agent administration device of the present invention, on the substrate made of the polysaccharide, after forming a plurality of pedestals made of the polysaccharide by mold molding, on the stage along the horizontal plane having an elevation control mechanism, The substrate was attached so that the pedestal points in a vertically downward direction, and the upper surface of the pedestal was brought into contact with the upper surface of the molten saccharide in a saccharide heating container whose temperature was controlled at 90 ° C. to 120 ° C. in a stationary state. Thereafter, the fine sugar needle was formed on the upper surface of the pedestal by moving the stage up and down, so that the effect of significantly reducing the cost was obtained. Further, in the production method of the present invention, it becomes possible to simultaneously mold a large number of fine sugar needles for forming a fine sugar needle by raising and lowering the stage once, It was possible to achieve mass production.

  In the functional agent administration device of the present invention, since a plurality of pedestals can be produced with high precision by using a mold, the number of pedestals on the substrate surface can be increased by increasing the number density per unit area by making the molds highly accurate. As a result, it was possible to obtain a highly integrated structure in which the number density of fine sugar needles per substrate unit area was high.

  In the method for producing a functional agent administration device of the present invention, a method in which fine saccharide needles are provided on a plurality of pedestals formed on a substrate is employed, so that the saccharide heating unit heats and melts the saccharide. Thus, the device structure can be simplified and the cost can be greatly reduced.

  Embodiments of the functional agent administration device, the production method thereof, and the production apparatus of the present invention will be described in detail below, but the present invention is not limited to the following embodiments.

  In the present invention, the fine saccharide needle means a fine needle composed of a saccharide, the functional agent means a nutrient or a pharmaceutical agent, and the functional agent administration device means an intradermal skin of the fine saccharide needle. It means a device that administers a nutrient or a pharmaceutical agent into the human body by dissolution in the skin after insertion or residue, and further means a jig for transdermally administering the nutrient or the like into the human body. That is, the functional agent administration device of the present invention is composed of a polysaccharide substrate, a plurality of polysaccharide pedestals provided on the substrate, and a fine saccharide needle provided on each pedestal. Is. FIG. 1 is a schematic view of a fine sugar needle provided on a substrate by a conventional stretching method, but the fine sugar needle 1 by a conventional stretching method using a nozzle is directly erected on a substrate 2. I understand that. As the material of the substrate 2, as described in the above-mentioned Patent Document 1, paper, tape, plasticity, or a metallic sheet that is adhesive and has heat resistance and stretchability has been used. The adhesion strength of the fine saccharide needle to the substrate was not sufficient, and therefore the fine saccharide needle was easily removed from the substrate, and was easily broken when inserted into the skin. Furthermore, even if the extrusion nozzles in the stretching method are processed with high accuracy, it is extremely difficult to integrate the nozzles with high accuracy to produce an extrusion nozzle mechanism. As shown in FIG. The fine sugar needle is opened and is erected on the substrate. In this case, high integration of the fine sugar needle itself is not desired. Therefore, it is not possible to expect an improvement in the dosage of a nutrient or the like with a fine sugar needle by a conventional stretching method using a nozzle.

  In the present invention, the substrate made of a polysaccharide is not particularly limited in size and shape when the substrate is viewed from directly above, and may be any size and shape as long as it is a substrate. As the polysaccharide, pullulan, carboxymethylcellulose, amylose, hyaluronic acid, chondroitin sulfate, glycosaminoglycan and the like can be used. In particular, pullulan and carboxymethylcellulose have high weldability and are safe and stable. It is suitable because it is highly productive and easily available. Next, pullulan, carboxymethylcellulose, amylose, hyaluronic acid, chondroitin sulfate, glycosaminoglycan and the like can be used as the polysaccharide for the pedestal comprising the polysaccharide in the present invention, and in particular, pullulan and carboxymethylcellulose are used. It is suitable for the reason that it has high weldability, high safety and stability, and is an easily available product. In addition, the same polysaccharide or different polysaccharides may be used for the material of the substrate and the pedestal (polysaccharide), but the same polysaccharide may be used when the substrate and the pedestal are manufactured integrally for cost reduction. Preferred. Next, in the present invention, the pedestal made of polysaccharide has a substantially cylindrical shape having a pedestal height of 10 μm to 2 mm, a pedestal top surface diameter of 30 μm to 1 mm, and a pedestal bottom surface diameter of 40 μm to 1.5 mm in contact with the substrate. Are preferably used. If this pedestal height is smaller than 10 μm, it is not preferable because it causes excessive cost to process the fine mold for forming the pedestal. If the pedestal height is larger than 2 mm, the pedestal and the fine carbohydrate are not preferred. This is not preferable because the needle becomes too large and loses fineness. Further, when the diameter of the upper surface of the pedestal is smaller than 30 μm, it is not preferable because it causes excessive cost for processing a fine mold for forming the pedestal, and when the diameter of the upper surface of the pedestal is larger than 1 mm, it is not preferable. This is not preferable because the drawing process for sharpening the tip of the fine sugar needle provided on the needle becomes difficult. Furthermore, when the diameter of the pedestal bottom surface is smaller than 40 μm, it is not preferable because it causes excessive cost to process a fine mold for pedestal molding, and when the diameter of the bottom surface is larger than 1.5 mm. Is not preferable because it is difficult to mold the pedestal upper surface within the range of 30 μm to 1 mm. The shape of the pedestal is not particularly limited, but from the viewpoint of easy processing and high processing accuracy, a substantially cylindrical shape or a substantially polygonal column shape described later is preferable. Incidentally, the substantially cylindrical shape and the substantially polygonal column shape in the present invention include a case where the upper area is larger or smaller than the bottom area in the cylinder or the polygonal column, and the same case is included. It should be noted that it is a polygonal prism.

  In the present invention, the fine sugar needle made of sugar has a substantially conical shape with a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface diameter of 30 μm to 1 mm in contact with the pedestal top surface, A bell shape or the like is preferably used. When the diameter of the needle tip is smaller than 0.5 μm, it is not preferable because it leads to excessive cost for ultra-fine stretching. When the diameter of the needle tip is larger than 20 μm, the needle tip is placed on the skin. It is not preferable because it is difficult to insert the needle and is painful when the needle is inserted. Further, when the needle length is smaller than 50 μm, it is not preferable because fine stretching of the needle tip is expensive, and when the needle length is larger than 2 mm, the needle diameter is increased by the stretching process. This is not preferable because the pain when the needle is inserted into the skin increases. Further, when the diameter of the bottom surface of the needle is smaller than 30 μm, it is not preferable because it becomes brittle when the needle is inserted into the skin. When the diameter of the bottom surface is larger than 1 mm, the fine sugar provided on the pedestal is not preferable. This is not preferable because it is difficult to sharply extend the tip of the quality needle. The shape of the fine saccharide needle is not particularly limited, but from the viewpoint of ease of processing by this production method and the pedestal upper surface having a substantially circular shape, a substantially conical shape, a bell shape, and a jewel shape are preferred. . Among these, the bell shape and the jewel shape have a larger volume of the fine sugar needle itself than the substantially conical shape, and are suitable for increasing the dosage of nutrients and the like. In addition to the numerical range of the size of the fine sugar needle described above, the maximum diameter of the substantially intermediate portion in the needle length direction is preferably 50 μm to 1.5 mm, but this maximum diameter is 50 μm. If the diameter is smaller, it is not preferable because the accuracy is limited in stretching to a fine curve, and if the maximum diameter is larger than 1.5 mm, it is not preferable because it causes pain when the needle is inserted into the skin. . Next, the carbohydrate of the fine sugar needle in the present invention is a nutrient that easily dissolves in the human body and is easily adapted to the living body, so that maltose as the main component, glucose, trehalose as the other component, etc. Saccharides are preferably used. FIG. 2 is a schematic view of the base on the substrate (substantially cylindrical shape) in the functional agent administration device of the present invention. In this figure, the base 3 made of a substantially columnar polysaccharide on the substrate 6 made of the polysaccharide. 9 are provided, and in each pedestal, the positional relationship between the pedestal top surface 4 and the pedestal bottom surface 5 is shown. These pedestals have a substantially cylindrical shape in which the upper surface of the pedestal has an area smaller than the bottom surface of the pedestal. FIG. 3 is a schematic view of a functional agent administration device having a substantially corn-shaped fine saccharide needle of the present invention. In this figure, a substantially cone is formed on each upper surface of the base 3 made of the polysaccharide shown in FIG. One fine sugar needle 7 having a shape is provided, and nine fine sugar needles 7 are shown. Next, FIG. 4 is a schematic view showing a cross section of the functional agent administration device in which the pedestal and the substrate are integrally manufactured with respect to the functional agent administration device of FIG. In FIG. 4, the pedestal and the substrate 8 manufactured in an integrated manner are shown. In this case, the substrate and the pedestal are made of the same polysaccharide material, so there is no boundary between the substrate and the pedestal, and they are integrated. Is shown. FIG. 5 is a schematic view showing a cross section of the functional agent administration device in which the pedestal and the substrate are separately manufactured with respect to the functional agent administration device of FIG. In FIG. 5, the separated substrate 10 and the separately produced pedestal 9 are shown. In this case, the substrate 10 and the pedestal 9 are made of different polysaccharide materials, and thus the substrate 10 and the pedestal 9 are attached to each other. Are bounded and they are shown separately, so the pedestal bottom 5 is clearly shown. Next, FIG. 6 is a schematic view of a functional agent administration device having a bell-shaped fine sugar needle of the present invention. In this figure, a bell shape is formed on each upper surface of the pedestal 3 made of the polysaccharide shown in FIG. The fine sugar needles 11 are provided one by one, and nine fine sugar needles 11 are shown. FIG. 7 is a schematic view of a functional agent administration device having a jewel-shaped fine saccharide needle of the present invention. In this figure, a jewel-shaped device is formed on each upper surface of the base 3 made of the polysaccharide shown in FIG. One fine sugar needle 12 is provided, and nine fine sugar needles 12 are shown.

  In the present invention, the pedestal made of polysaccharide is inscribed or circumscribed in a circle having a pedestal height of 10 μm to 2 mm and a top surface of the pedestal of 30 μm to 1 mm as a different aspect from the above substantially cylindrical pedestal, A base having a substantially polygonal column shape in which the pedestal bottom contacting the substrate is inscribed or circumscribed in a circle having a diameter of 40 μm to 1.5 mm is preferably used. If this pedestal height is smaller than 10 μm, it is not preferable because it causes excessive cost to process the fine mold for forming the pedestal. If the pedestal height is larger than 2 mm, the pedestal and the fine carbohydrate are not preferred. This is not preferable because the needle becomes too large and loses fineness. Further, when the diameter of the circle inscribed or circumscribed by the upper surface of the pedestal is smaller than 30 μm, it is not preferable because of excessive cost for processing the fine mold for forming the pedestal, and the diameter of the circle is less than 1 mm. In the case where it is large, it is not preferable because the drawing process for sharpening the tip of the fine sugar needle provided on the pedestal becomes difficult. Furthermore, when the diameter of the circle inscribed or circumscribed by the base of the pedestal is smaller than 40 μm, it is not preferable because it causes excessive cost to process a fine mold for forming the pedestal, and the diameter of the circle is not preferable. When the diameter is larger than 1.5 mm, it is not preferable because it is difficult to mold the pedestal upper surface within the range of 30 μm to 1 mm. The shape of the pedestal is not particularly limited, but from the viewpoint of easy processing and high processing accuracy, the above-described substantially cylindrical shape or substantially polygonal column shape is preferable. Next, in the present invention, the fine saccharide needle made of saccharide has a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a substantially polygonal pyramid shape in which the needle bottom is the same shape as the top surface of the pedestal. A substantially bell shape or the like is preferably used. The reason for these preferable numerical ranges is the same as described above. The shape of the fine saccharide needle is not particularly limited, but from the viewpoint of ease of processing by this production method and the pedestal upper surface being a substantially polygonal shape, a substantially polygonal pyramid shape, a substantially bell shape, and a substantially jewel shape are Is preferred. Among these, the substantially bell shape and the substantially jewel shape have a larger volume of the fine sugar needle itself than the substantially polygonal pyramid shape, and are suitable for increasing the dosage of nutrients and the like. In addition to the size and shape of the fine sugar needle described above, the substantially jewel shape is a substantially polygonal shape in which a substantially middle portion in the needle length direction is inscribed or circumscribed to a circle having a diameter of 50 μm to 1.5 mm. However, when the diameter is smaller than 50 μm, it is not preferable because the accuracy is limited in drawing to a fine curve, and when the diameter is larger than 1.5 mm, it is not preferable. It is not preferable because it is painful when the skin is inserted. In addition, the fact that the substantially middle part in the needle length direction is a substantially polygon that is inscribed or circumscribed to a circle having a diameter of 50 μm to 1.5 mm means that the fine sugar needle is cut in a horizontal plane at the position of the substantially middle part. This means that the cross section is substantially polygonal and that this polygon is inscribed or circumscribed to a circle having a diameter of 50 μm to 1.5 mm. Further, in this fine sugar needle, the cross-section when the above-mentioned bell-shaped and jewel-shaped fine sugar needles are cut in a horizontal plane is substantially circular (because the upper surface of the base is substantially circular), The cross section when the substantially bell shape and the approximately jewel shape are similarly cut is substantially polygonal (because the upper surface of the pedestal is approximately polygonal), and therefore in the present invention, it is described as the approximately bell shape and approximately jewel shape. Note that. FIG. 8 is a schematic view of a functional agent administration device having a fine saccharide needle having a substantially quadrangular pyramid shape according to the present invention. In FIG. One pyramid-shaped fine sugar needle 13 is provided, and nine of the fine sugar needles 13 are shown. Next, FIG. 9 is a schematic view of a functional agent administration device having a substantially bell-shaped fine sugar needle of the present invention. In this figure, a substantially bell is formed on each upper surface of the pedestal 3 made of a polysaccharide having a substantially quadrangular prism shape. One fine sugar needle 14 having a shape is provided, and nine of the fine sugar needles 14 are shown. FIG. 10 is a schematic diagram of a functional agent administration device having a substantially jewel-shaped fine sugar needle of the present invention. In this figure, a substantially jewel-shaped shape is formed on each upper surface of a base 3 made of a substantially quadrangular prism-shaped polysaccharide. The fine sugar needles 15 are provided one by one, and nine fine sugar needles 15 are shown.

  In the present invention, the nutrients contained in the sugar of the fine sugar needle include vitamin A, vitamin B complex, vitamin C, vitamin D, vitamin E, vitamin K, glutamine, essential amino acid, non-essential amino acid, γ-amino. One or more nutrients selected from butyric acid, taurine, fatty acids, nucleic acids, and adrenaline are preferred. In particular, vitamin A such as retinol and retinal, thiamine, riboflavin, niacin, adenine, pantothenic acid, pyridoxine, pyridoxamine, biotin, adenylic acid, folic acid, folic acid and a mixture of other vitamin B compounds, vitamin S, cyanocobalamin, pyrimidine- 5-carboxylic acid, vitamin B-14 and a mixture of B-10 and B-11, dimethylglycine, amygdalin, vitamin B-22, folic acid, vitamin B-9, inositol, L-carnitine, biotin, paraaminobenzoic acid, etc. Vitamin B complex, vitamin C such as L-ascorbic acid, vitamin D such as ergocalciferol, vitamin E such as tocopherol, vitamin K such as phylloquinone, tryptophan, lysine, methionine, phenylalanine, threonine Essential amino acids such as isoleucine, leucine and histidine, non-essential amino acids such as alanine, arginine, aspartic acid, serine, cysteine, glutamine, glycine, proline and tyrosine, fatty acids such as taurine such as aminoethyl sulfonic acid, butanoic acid and hexadocosanoic acid , Nucleic acids such as DNA and RNA, adrenaline such as catecholamine, and the like can be suitably used. In addition, there is no particular limitation on the method of adding a nutrient to the sugar of the fine sugar needle, but after mixing the nutrient with the sugar raw material of the fine sugar needle, the heated and melted mixture is made into a fine sugar needle. There is a method, a method of mixing the nutrient with the heated and melted carbohydrate raw material, and then making the heated melt mixture into a fine sugar needle, etc., but any method as long as it does not impair the function of the nutrient But it ’s okay.

  In the present invention, the pharmaceutical agent contained in the carbohydrate of the fine saccharide needle includes an analgesic agent, an anti-inflammatory agent, an antipyretic analgesic / anti-inflammatory agent, an antifungal agent, an antibacterial agent, an antiviral agent, a cardiotonic agent, a thrombolytic agent, a hemostatic agent, 1 doctor selected from diuretics, antihypertensives, anesthetics, sedatives, sleeping pills, anticonvulsants, anxiolytics, anti-anxiety drugs, tranquilizers, antidepressants, sleep sedatives, antiprotozoal drugs Preferably it is a drug. In particular, analgesics such as acetaminophen, salicylate, morphine, aspirin, salicylic acid, diclofenac, indomethacin, ibuprofen, ketoprofen, naproxen, piroxicam, antipyretic analgesics such as acetaminophen, amphotericin B, flucytosine, Antifungal agents such as econazole, miconazole, fluconazole, itraconazole, micafungin, terbinafine hydrochloride, rylanaphthalate, butenafine, amorolfine, griseofulvin, antibacterial agents such as sulfamethizole, benzylpenicillin, chlorotetracycline, chloramphenicol, acyclobeer, Antiviral drugs such as ganciclovir and Foscarnet, cardiotonic drugs such as digitalis, heparin, warfarin, uroki Thrombolytic agents such as sesame, hemostatic agents such as tranexamic acid and collagen, concentrated glycerin, hydrochlorothiazide, trichlormethiazide, indapamide, chlorthalidone, spironolactone canrenoic acid potassium, eplerenone, acetazolamide, dopamine hydrochloride, aminophylline, carperitide, hydrochloric acid Diuretics such as chlorpromazine, anti-hypertensives such as trichlormethiazide, hydrochlorothiazide, furosemide, bumetanide, ethacrynic acid, spironolactone, triamterene, amlodipine, diltiazem, anesthetics such as fentanyl citrate, benzodiazepine, diazebam, promethazine hydrochloride, lidocaine, thiopetal Sleepers such as sedatives such as triazolam, exolam, bentobarbital, flunitrazebum, flurazebam Drugs, anticonvulsants such as phenobarbital, anti-anxiety drugs such as exolam, lorazebum, cloxazolam, and prazebam, anti-anxiety drugs such as diphenhydramine hydrochloride, promethazine hydrochloride, loratadine, tranquilizers such as meji tranquilizer, proppropion hydrochloride, Antidepressants such as trazodone hydrochloride and sulpiride, sleep sedatives such as triazolam, estazolam, amobarbital, zolvidem tartrate, antiprotozoal drugs such as sulfadoxine-pyrimethamine, and the like can be suitably used. The method for containing the pharmaceutical agent in the saccharide of the fine saccharide needle is not particularly limited, but after mixing the pharmaceutical agent with the saccharide raw material of the fine saccharide needle, the heated melt mixture is made into a fine saccharide needle. There is a method, a method of mixing the pharmaceutical agent with a heated and melted saccharide raw material, and then making the heated molten mixture into a fine saccharide needle, and any method as long as it does not impair the function of the pharmaceutical agent But it ’s okay.

  In the method for producing a functional agent administration device of the present invention, a plurality of pedestals made of the above-mentioned polysaccharides by molding are formed on the substrate made of the above-mentioned polysaccharides, and then have an elevation control mechanism and follow a horizontal plane. On the stage, the substrate is attached so that the pedestal points in the vertically downward direction, and the upper surface of the pedestal is placed on the upper surface of the molten saccharide in the saccharide heating container whose temperature is controlled to 90 ° C. to 120 ° C. After the contact, the fine sugar needle is preferably formed on the upper surface of the pedestal by raising and lowering the stage. As the above-described lift control mechanism, a control mechanism using a step motor capable of fine digital driving can be suitably used because fine vertical controllability is necessary. As the sugar heating container, a stainless steel heating container having a constant temperature characteristic can be suitably used because it stably maintains the sugar melting temperature. Furthermore, when the control temperature of the sugar heating container is lower than 90 ° C., it is not preferable because the saccharide is not sufficiently melted and a solidified part remains, and when the control temperature is higher than 120 ° C., It is not preferable because the quality is denatured. In addition, maltose which is a main component of a carbohydrate that can be preferably used in the present invention, among glucose or trehalose as another component, maltose as a main component and glucose as another component are in a molten state within the above temperature control range. However, the other component trehalose does not melt, so that the sugar mixture of maltose and trehalose is a mixture of crystalline trehalose in the molten maltose within the above temperature control range. Further, in the present invention, any of the above-mentioned nutrients and pharmaceutical agents that can be suitably contained in the sugar of the fine sugar needle can be maintained within the above temperature control range and can retain their functions. It is.

  In the method for producing a functional agent administration device of the present invention, the control method for finely adjusting the moving speed of the stage ascending / descending by arbitrarily dividing the moving distance of the stage in a digital manner and arbitrarily changing the moving distance of the stage Thus, it is preferable to mold the fine sugar needle on the pedestal upper surface with high accuracy. As the control method for finely adjusting the moving speed, a numerical control (NC control) method for obtaining and driving a predetermined signal from a computer can be suitably used because the speed needs to be varied. In the functional agent administration device of the present invention, when controlling the shape of the fine saccharide needle, the upper surface of the pedestal is brought into contact with the molten saccharide upper surface, and then the stage is raised at a high speed to thereby finely adjust the shape of the fine saccharide needle. The sugar needle has a shape with a high aspect ratio (thin and long), while the fine sugar needle has a shape with a low aspect ratio (thick and short) by raising the stage at a low speed. That is, by controlling the ascending speed of the stage at a high speed or a low speed, when the pedestal top surface is circular, the aspect ratio is high or low, resulting in a cone-shaped fine sugar needle, and when the pedestal top surface is polygonal, the aspect ratio It becomes a fine sugar needle of a polygonal pyramid shape with a high or low ratio. In addition, when the ascending speed of the stage is slow from the initial stage to the middle stage and is controlled at a high speed in the late stage, if the pedestal upper surface is circular, it becomes a bell-shaped fine sugar needle, and the pedestal upper surface is polygonal Becomes a fine sugar needle with a substantially bell shape. Furthermore, it is possible to increase the width of the fine sugar needle by temporarily raising and stopping the stage and then lowering the stage, and by performing such an elevation control of the stage, The curved lower part in the above-mentioned jewel, approximately jewel shape can be molded, and then the stage is raised at a constant speed, so that when the pedestal upper surface is circular, it becomes a jewel-shaped fine sugar needle, and the pedestal upper surface When is a polygonal shape, it becomes a fine sugar needle having a substantially jewel shape. In short, in the method for producing a functional agent administration device of the present invention, as described above, the shape of the fine sugar needle can be variously controlled by performing predetermined elevation control by combining the elevation control of the stage variously. Is possible.

  In the functional agent administration device manufacturing apparatus of the present invention, the carbohydrate heating container having a temperature control mechanism of 90 ° C. to 120 ° C., and the elevation control capable of attaching the substrate so that the pedestal points in the vertically downward direction Preferably, the stage includes a mechanism along a horizontal plane, and further includes the stage having an alignment control mechanism that arbitrarily positions a distance between the upper surface of the base and the upper surface of the molten carbohydrate. As the sugar heating container, as described above, a stainless steel heating container having a constant temperature characteristic or the like can be suitably used because it stably maintains the sugar melting temperature. In addition, this alignment control mechanism is capable of detecting a fine position, for example, detecting the interference intensity of a laser beam that fluctuates depending on the wavelength size, an encoder that uses light, and a caliper for a mechanical type. An alignment control device using a mechanism or the like can be suitably used. FIG. 11 is a schematic diagram showing a state in the process of producing a fine sugar needle by a fine sugar needle manufacturing apparatus based on a conventional stretching method. In FIG. 11, this is provided in the molten sugar material supply machine 17. After the molten sugar material 19 is pushed out from the two nozzles 18 onto the substrate 2 heated by the substrate heater 20, the molten sugar material 19 is stretched by the elevation control mechanism 16 of the molten sugar material supply machine. 2 shows a state in which two of the fine sugar needles 1 are being produced. On the substrate 2, two fine sugar needles 1 have been produced, and two of them are being produced. Has been. In the conventional fine sugar needle manufacturing apparatus based on such a stretching method, it is difficult to provide the high-precision processed nozzle 18 in the molten sugar material supply machine 17 and the cost is correspondingly high. It can be understood that it is difficult to fabricate a quality needle on the substrate 2. Incidentally, in FIG. 11, in order to clarify the saccharide material, the saccharide material is illustrated with shading by dot display, but this is the same in FIGS. 12 and 13 below. FIG. 12 is a schematic diagram showing a state in the process of producing a fine sugar needle by the apparatus for producing a functional agent administration device of the present invention. In this figure, on the substrate 6 made of a polysaccharide, the mold is molded. After the three pedestals 3 made of the polysaccharides are molded, the substrate 6 is mounted on the substrate mounting stage 22 that has the elevation control mechanism 21 of the substrate mounting stage along the horizontal plane so that the pedestal 3 points in the vertically downward direction. After the upper surface of the pedestal 3 is brought into contact with the upper surface of the molten saccharide (the molten saccharide material 19) in the saccharide heating container 23 whose temperature is controlled to 90 ° C. to 120 ° C. in a stationary state, the stage A state in which three fine sugar needles are being produced on the upper surface of the pedestal 3 by moving up and down 22, that is, three fine sugar needles 24 in the middle of stretching the molten sugar material are shown. Incidentally, in this figure, the stage 22 serves as an alignment control mechanism for arbitrarily positioning the distance between the pedestal 3 and the upper surface of the molten saccharide (the molten saccharide material 19). Although it has a mechanism 25, it should be noted that the control mechanism 25 schematically shows a state in which the reciprocating laser beam 26 is irradiated vertically downward to position the distance. The reciprocating laser beam 26 is used for arbitrarily positioning the distance between the pedestal upper surface 4 and the upper surface of the molten sugar material 19. Instead, as shown in FIG. 12, the stage surface (the surface on which the substrate is not attached) is irradiated with a reciprocating laser beam to measure the stage position. For example, the upper surface of the pedestal is left stationary. The stage position at the time of contact with the upper surface of the molten sugar in the state is measured by the reciprocating laser beam 26 as a reference position, and the movement distance of the pedestal from the reference position is measured using the alignment control mechanism 25 by laser beam interference. Just fine-tune. The control mechanism 25 controls the raising / lowering of the stage position, that is, the raising / lowering of the pedestal upper surface 4 in contact with the molten sugar material 19, so that the shape of the fine sugar needle is substantially cone, bell, jewel, It will be made in the shape of a polygonal pyramid, an approximate bell, and an approximate jewel. Furthermore, FIG. 13 is a schematic diagram showing a completed production state of a fine sugar needle by the apparatus for manufacturing a functional agent administration device of the present invention. In this figure, the upper surface of the pedestal 3 is lifted by moving the stage 22 up and down. 3 shows a completed state in which three fine sugar needles are produced, that is, three fine sugar needles 27 by stretching a molten sugar material. As described above, in the apparatus for manufacturing a functional agent administration device of the present invention, the nozzle for extruding the molten sugar material, which was necessary in the conventional stretching method, is completely unnecessary. In addition, a large number of the fine sugar needles 27 can be easily manufactured with high accuracy on the base 3 provided on the substrate 6.

  EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to the following examples.

Preparation of nutritional administration device and insertion test in skin In order to integrally manufacture pedestal and substrate, on a substrate made of pullulan (a square shape of 5 mm in length and width, thickness 500 μm) by a predetermined mold forming process, Three pedestals made of pullulan (substantially cylindrical, pedestal height 100 μm, pedestal top diameter 300 μm, pedestal bottom diameter 400 μm) in three rows and three rows in each row at a pitch of 1 mm. A total of nine were produced (the outline of the outline is as shown in FIG. 2). The board | substrate with which these bases were provided was attached to the stage which has a raising / lowering control mechanism and follows a horizontal surface so that these bases may point a perpendicular downward direction. Next, after these upper surfaces of the pedestal are brought into contact with the upper surface of the molten saccharide (using maltose in this embodiment) in a saccharide heating container whose temperature is controlled to 100 ° C. in a stationary state, the stage is moved to a predetermined state. By controlling the elevation, fine sugar needles (in a substantially conical shape, having a needle tip diameter of 5 μm, a needle length of 600 μm, and a needle bottom diameter of 300 μm) are simultaneously molded one by one, that is, A nutrient solution administration device having nine fine sugar needles at a time was prepared (the outline of the outline and the cross section is as shown in FIGS. 3 and 4). In addition, the schematic diagram which shows the outline of the manufacturing method and manufacturing apparatus in a present Example is as having shown by FIG.12 and FIG.13, and a predetermined signal is obtained from the computer in the control method which finely adjusts stage raising / lowering. A positioning control mechanism that uses the detection of the interference intensity of laser light is used for the positioning control mechanism that arbitrarily positions the distance between the top surface of the pedestal and the top surface of the melted carbohydrate by using a numerical control method for driving. The same applies to Examples 2 to 12 below. However, it should be noted that in FIG. 12 and FIG. 13, a substantially conical fine sugar needle is illustrated for the sake of simplicity. Next, in order to perform an intradermal insertion test on this nutrient solution administration device, the opposite ends of the substrate are sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the fine carbohydrate is placed on the left arm upper arm skin site of the subject. When the fine saccharide needle is inserted into the skin by pressing the skin part with this nutrient solution administration device so that the needle hits, the skin can be inserted painlessly and all fine saccharide needles remain in the skin. (That is, about 0.13 mg of maltose was administered into the body). In this skin insertion test, the fine sugar needle remaining in the skin dissolves and is absorbed into the body as a nutrient, and when the nutrient administration device is pulled away from the skin site after insertion, the skin Although no scar was left on the site, these were the same in Examples 1 to 6 below.

Preparation of nutrient solution administration device and skin insertion test In order to separate and manufacture the pedestal and the substrate, a predetermined mold molding process was carried out on a substrate made of pullulan (a square shape 5 mm in length and width, thickness 500 μm). Pedestals made of methylcellulose (CMC) (substantially cylindrical, with a pedestal height of 100 μm, a pedestal top diameter of 300 μm, and a pedestal bottom diameter of 400 μm) are arranged in 3 rows and 3 rows in a 1 mm pitch interval in each row. Nine pieces were produced in total (three outlines as outlined in FIG. 2). The board | substrate with which these bases were provided was attached to the stage which has a raising / lowering control mechanism and follows a horizontal surface so that these bases may point a perpendicular downward direction. Next, the top surface of these pedestals was allowed to stand in a stationary state at a temperature of 95 ° C. in a heated saccharide container (in this example, a sugar mixture in which 10% by weight glucose was mixed with maltose was used). After making contact with the upper surface, the stage is controlled to move up and down in a predetermined manner, whereby fine sugar needles (with a bell shape, a needle tip diameter of 7 μm, a needle length of 600 μm, and a needle bottom surface diameter of 300 μm are controlled on the pedestal. One) was molded at a time, that is, a nutrient administration device having nine fine saccharide needles at a time (the outline of the outline was as shown in FIG. 6). Next, in order to conduct a skin insertion test on the nutrient solution administration device, when a fine saccharide needle was inserted into the skin in the same manner as in Example 1, it was possible to insert the skin in a painless state, and all the fine sugars entered the skin. The needle could be left (ie, about 0.17 mg of maltose and about 0.02 mg of glucose administered simultaneously in the body).

Preparation of nutritional administration device and insertion test in skin In order to integrally manufacture pedestal and substrate, on a substrate made of pullulan (a square shape of 5 mm in length and width, thickness 500 μm) by a predetermined mold forming process, Three pedestals made of pullulan (substantially cylindrical, pedestal height 100 μm, pedestal top diameter 300 μm, pedestal bottom diameter 400 μm) in three rows and three rows in each row at a pitch of 1 mm. A total of nine were produced (the outline of the outline is as shown in FIG. 2). The board | substrate with which these bases were provided was attached to the stage which has a raising / lowering control mechanism and follows a horizontal surface so that these bases may point a perpendicular downward direction. Next, the molten sugar in a sugar heating container whose temperature is controlled to 110 ° C. with the pedestal upper surface being stationary (in this example, a sugar mixture in which 3 wt% trehalose is mixed with maltose is used) After making contact with the upper surface, the stage is controlled to move up and down in a predetermined manner, whereby fine sugar needles (in the shape of jewels, with a needle tip diameter of 7 μm, a needle length of 600 μm, a needle bottom diameter of 300 μm, (The maximum diameter of the substantially middle part in the needle length direction is 500 μm), one by one, that is, a nutrient administration device having nine fine sugar needles at a time is manufactured (the outline of the outline is shown in FIG. 7). As indicated). Next, in order to conduct a skin insertion test on the nutrient solution administration device, when a fine saccharide needle was inserted into the skin in the same manner as in Example 1, it was possible to insert the skin in a painless state, and all the fine sugars entered the skin. The needle could be left (ie, about 0.2 mg of maltose and about 6 μg of trehalose were administered simultaneously in the body).

Preparation of nutritional administration device and insertion test in skin In order to integrally manufacture pedestal and substrate, on a substrate made of pullulan (a square shape of 5 mm in length and width, thickness 500 μm) by a predetermined mold forming process, A pedestal made of pullulan (substantially square column shape, pedestal height 100 μm, inferior to a circle having a diameter of 424 μm, a substantially square pedestal top surface with a side of 300 μm, and a bottom surface of a substantially square pedestal with 400 μm side inscribed in a circle with a diameter of 565 μm. ) Was produced in a total of 9 pieces in 3 rows and 3 rows in each row at a pitch of 1 mm. The board | substrate with which these bases were provided was attached to the stage which has a raising / lowering control mechanism and follows a horizontal surface so that these bases may point a perpendicular downward direction. Next, these pedestal upper surfaces were allowed to stand, and the molten sugar in a sugar heating container whose temperature was controlled at 100 ° C. (in this example, maltose was mixed with 5 wt% magnesium ascorbate phosphate (vitamin C)). After making contact with the upper surface of the sample, the stage is controlled to move up and down in a predetermined manner, so that fine sugar needles (approximately quadrangular pyramid shape, needle tip diameter of 5 μm, needle length) 600 μm, the bottom of the needle is the same square shape as the top of the pedestal), one by one, that is, a nutrient administration device having nine fine sugar needles at a time (the outline of the outline is shown in the figure) 8). Next, in order to conduct a skin insertion test on the nutrient solution administration device, the opposite ends of the substrate are sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the fine sugar is applied to the spot on the subject's face skin. When the fine sugar needle is inserted into the facial skin by pressing the stain site with this nutrient solution administration device so that the needle touches, the skin can be inserted painlessly, and all fine sugar needles are placed in the facial skin. (Ie, about 0.16 mg of maltose and about 8 μg of magnesium ascorbate phosphate were simultaneously administered into the facial skin). Further, when this intradermal insertion test was continued once a week for 3 months, it was confirmed that the above-mentioned vitamin C administration had an effect of thinning the stain site to an inconspicuous place.

Preparation of nutritional administration device and insertion test in skin In order to integrally manufacture pedestal and substrate, on a substrate made of pullulan (a square shape of 5 mm in length and width, thickness 500 μm) by a predetermined mold forming process, A pedestal made of pullulan (substantially square column shape, pedestal height 100 μm, inferior to a circle having a diameter of 424 μm, a substantially square pedestal top surface with a side of 300 μm, and a bottom surface of a substantially square pedestal with 400 μm side inscribed in a circle with a diameter of 565 μm. ) Was produced in a total of 9 pieces in 3 rows and 3 rows in each row at a pitch of 1 mm. The board | substrate with which these bases were provided was attached to the stage which has a raising / lowering control mechanism and follows a horizontal surface so that these bases may point a perpendicular downward direction. Next, molten saccharides in a saccharide heating container whose temperature is controlled to 100 ° C. with the pedestal upper surface stationary (in this example, maltose containing 10 wt% retinol (vitamin A) is used. ), The stage is controlled to move up and down in a predetermined manner, whereby a fine sugar needle (substantially bell-shaped, needle tip diameter 7 μm, needle length 600 μm, needle bottom The same shape as the upper surface of the pedestal is formed at the same time, ie, a nutrient administration device having nine fine sugar needles at a time (the outline of the outline is shown in FIG. 9). Street). Next, in order to perform an intradermal insertion test on this nutrient solution administration device, the opposite ends of the substrate are sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the fine carbohydrate is placed on the left arm upper arm skin site of the subject. When the fine saccharide needle is inserted into the skin by pressing the skin part with this nutrient solution administration device so that the needle hits, the skin can be inserted painlessly and all fine saccharide needles remain in the skin. (That is, about 0.19 mg of maltose and about 20 μg of retinol were simultaneously administered into the body).

Preparation of nutritional administration device and insertion test in skin In order to integrally manufacture pedestal and substrate, on a substrate made of pullulan (a square shape of 5 mm in length and width, thickness 500 μm) by a predetermined mold forming process, A pedestal made of pullulan (in the shape of a substantially quadrangular prism, a pedestal height of 100 μm, a square pedestal with a side of 300 μm inscribed in a circle with a diameter of 424 μm, and a square pedestal bottom with a side of 400 μm inscribed in a circle with a diameter of 565 μm) A total of 9 pieces were produced, 3 in each row and 3 in each row at a pitch of 1 mm in 3 rows and 3 rows. The board | substrate with which these bases were provided was attached to the stage which has a raising / lowering control mechanism and follows a horizontal surface so that these bases may point a perpendicular downward direction. Next, molten saccharides (in this example, maltose containing 10% by weight niacin (vitamin B complex) in a saccharide heating container whose temperature was controlled at 95 ° C. while the upper surfaces of the pedestals were allowed to stand were controlled. Are used, and the stage is controlled to be moved up and down in a predetermined manner, whereby fine sugar needles (substantially jewel-shaped, needle tip diameter of 7 μm, needle length of 600 μm, needles) The bottom surface is substantially the same square shape as the top surface of the pedestal, and the substantially middle portion in the needle length direction is a substantially square having a side of 500 μm inscribed in a circle having a diameter of 707 μm). A nutrient solution administration device having a fine saccharide needle was prepared (the outline of the outline was as shown in FIG. 10). Next, in order to conduct a skin insertion test on the nutrient solution administration device, when a fine saccharide needle was inserted into the skin in the same manner as in Example 5, it was possible to insert the skin in a painless state, and all the fine sugars entered the skin. The needle could be left (ie, about 0.23 mg maltose and about 25 μg niacin administered simultaneously in the body).

Production of pharmaceutical agent administration device and insertion test into skin In the same manner as in Example 1, a pedestal and a substrate were integrally manufactured, and a substrate provided with these nine pedestals was provided with a lift control mechanism along a horizontal plane. These pedestals were attached so as to point in the vertically downward direction. Next, melted saccharides in a saccharide heating container whose temperature is controlled to 100 ° C. with the pedestal upper surface stationary (in this example, maltose containing 1 wt% indomethacin (anti-inflammatory drug)) is used. ), The stage is controlled to move up and down in a predetermined manner, so that fine sugar needles (approximately conical shape, needle tip diameter 5 μm, needle length 600 μm, needle bottom surface) (With a diameter of 300 μm) are molded at the same time, that is, a pharmaceutical agent administration device having nine fine sugar needles at a time is produced (the outline and cross section are schematically shown in FIGS. 3 and 4). did. Next, in order to conduct an intradermal insertion test for the pharmaceutical agent administration device, the opposite arm of the substrate is sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the left upper arm skin with pain due to the subject's bruise When the fine saccharide needle is inserted into the skin by pressing the skin part with the present pharmaceutical agent administration device so that the fine saccharide needle hits the part, the skin can be inserted painlessly, and all fine saccharides in the skin The needle was allowed to remain (ie, about 0.13 mg maltose and about 1.3 μg indomethacin were administered into the body). In addition, the pain due to the subject's bruise was gradually relieved for a while after the intradermal insertion test, and the anti-inflammatory effect of indomethacin was confirmed. According to this intradermal insertion test, the main component of the fine sugar needle remaining in the skin is dissolved, and the nutrient and pharmaceutical agent are absorbed into the body, and after the insertion, the pharmaceutical agent administration device is removed from the skin site. When pulled apart, no scars were left on the skin site, but these were the same in Examples 7 to 12 below.

Preparation of pharmaceutical agent administration device and skin insertion test In the same manner as in Example 2, the pedestal and the substrate were separately manufactured, and the substrate provided with these nine pedestals was placed on a stage having a lifting control mechanism along a horizontal plane. These pedestals were attached so as to point vertically downward. Next, molten saccharides in a saccharide heating container whose temperature is controlled to 100 ° C. with the pedestal upper surface being stationary (in this embodiment, maltose containing 1 wt% lidocaine (anesthetic agent) is used. ) And then the stage is controlled to move up and down in a predetermined manner, whereby fine sugar needles (with a bell shape, needle tip diameter 7 μm, needle length 600 μm, needle bottom diameter) 300 μm) were simultaneously molded one by one, that is, a pharmaceutical agent administration device having nine fine sugar needles at a time was produced (the outline of the outline is as shown in FIG. 6). Next, in order to perform an intradermal insertion test on this pharmaceutical agent administration device, the opposite ends of the substrate are sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the fine sugar is placed on the skin of the right arm upper arm of the subject. When the fine saccharide needle is inserted into the skin by pressing the skin site with this pharmaceutical agent administration device so that the needle hits, the skin can be inserted painlessly and all fine saccharide needles remain in the skin. (That is, about 0.16 mg of maltose and about 1.6 μg of lidocaine were simultaneously administered into the body). In addition, after this intracutaneous test, the sensation of the skin part of the subject gradually became paralyzed, and the anesthetic effect by lidocaine was confirmed.

Preparation of pharmaceutical agent administration device and insertion test in skin In the same manner as in Example 3, a base and a substrate were manufactured in an integrated manner, and the substrate provided with these nine bases was provided with a lift control mechanism along a horizontal plane. These pedestals were attached so as to point in the vertically downward direction. Next, these pedestal upper surfaces were allowed to stand in a stationary state and were heated in a sugar-heated container whose temperature was controlled to 95 ° C. (in this example, maltose contained 1% by weight diphenhydramine hydrochloride (sickness medicine)) Are used, and the stage is controlled to move up and down in a predetermined manner, whereby fine sugar needles (jewel-shaped, needle tip diameter 7 μm, needle length 600 μm, needle bottom surface) Each having a diameter of 300 μm and a maximum diameter of approximately the middle part in the needle length direction of 500 μm), one at a time, that is, producing a pharmaceutical agent administration device having nine fine sugar needles at one time The outline is as shown in FIG. Next, in order to conduct an intracutaneous insertion test for this pharmaceutical agent administration device, the opposite arm of the substrate is sandwiched between two fingers so that the finger does not touch the fine sugar needle, and the left arm upper arm skin of a subject who is intoxicated When the fine saccharide needle is inserted into the skin by pressing the skin part with the present pharmaceutical agent administration device so that the fine saccharide needle hits the part, the skin can be inserted painlessly, and all fine saccharides in the skin The needle was allowed to remain (ie, about 0.19 mg maltose and about 1.9 μg diphenhydramine hydrochloride were administered simultaneously in the body). In addition, after the insertion test in the skin, the car sickness of the subject gradually improved after a while, and the effect of sickness prevention by diphenhydramine hydrochloride was confirmed.

Production of pharmaceutical agent administration device and insertion test in skin In the same manner as in Example 4, a base and a substrate are manufactured integrally, and a substrate provided with these nine bases is provided with a lift control mechanism and a stage along a horizontal plane. These pedestals were attached so as to point in the vertically downward direction. Next, these pedestal upper surfaces were allowed to stand in a stationary state and heated in a sugar heating container whose temperature was controlled at 100 ° C. (in this example, maltose containing 1 wt% urokinase (thrombolytic agent)) After making contact with the upper surface of the use, the stage is controlled to move up and down in a predetermined manner, whereby a fine carbohydrate needle (approximately quadrangular pyramid shape, needle tip diameter 5 μm, needle length 600 μm, The bottom surface is substantially the same square shape as the top surface of the pedestal, and is simultaneously molded one by one, that is, a nutrient administration device having nine fine sugar needles at a time is produced (the outline of the outline is shown in FIG. 8). As you did). Next, in order to perform an intracutaneous insertion test on this pharmaceutical agent administration device, the opposite ends of the substrate are sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the fine sugar is applied to the skin region of the subject's face cheek. When the fine saccharide needle is inserted into the buccal skin while pressing the skin part with this pharmaceutical agent administration device so that the needle touches, the skin can be inserted painlessly, and all the fine saccharide needles are placed in the buccal skin. Could be left (ie, about 0.15 mg maltose and about 1.5 μg urokinase administered simultaneously in the buccal skin). In addition, after the intradermal test, the thrombus dissolution phenomenon could be observed by microscopic observation of blood collected at the cheek skin site, and the thrombolytic effect of urokinase was confirmed.

Preparation of pharmaceutical agent administration device and insertion test into skin In the same manner as in Example 5, the pedestal and the substrate were integrally manufactured, and the substrate provided with these nine pedestals was equipped with a lift control mechanism along a horizontal plane. These pedestals were attached so as to point in the vertically downward direction. Next, molten sugar in a sugar heating container whose temperature is controlled to 95 ° C. with the upper surface of the pedestal stationary (in this example, maltose containing 1 wt% triazolam (sleeping medicine) is used) After making contact with the upper surface of the needle, the stage is controlled to move up and down in a predetermined manner, whereby fine sugar needles (approximately bell-shaped, needle tip diameter 7 μm, needle length 600 μm, needle bottom surface The same shape as the upper surface of the pedestal is formed at the same time, that is, a nutrient administration device having nine fine sugar needles at a time is manufactured (the outline of the outline is as shown in FIG. 9). )did. Next, in order to perform an intradermal insertion test for this pharmaceutical agent administration device, the opposite ends of the substrate are sandwiched with two fingers so that the finger does not touch the fine sugar needle, and the fine sugar is placed on the left arm upper arm skin site of the subject. When the fine saccharide needle is inserted into the skin by pressing the skin site with this pharmaceutical agent administration device so that the needle hits, the skin can be inserted painlessly and all fine saccharide needles remain in the skin. (That is, about 0.18 mg of maltose and about 1.8 μg of triazolam were simultaneously administered into the body). In addition, 60 minutes after the completion of the intradermal insertion test, the subject felt sleepy and slept for a while, and the sleep effect of triazolam was confirmed.

Preparation of pharmaceutical agent administration device and insertion test into skin In the same manner as in Example 6, the pedestal and the substrate were integrally manufactured, and the substrate provided with these nine pedestals was equipped with a lift control mechanism along a horizontal plane. These pedestals were attached so as to point in the vertically downward direction. Next, the top surface of these pedestals was allowed to stand, and the molten sugar in a sugar heating container whose temperature was controlled to 95 ° C. (in this example, maltose was allowed to contain 1 wt% trichloromethiazide (antihypertensive agent)). After making contact with the upper surface of the material used), the stage is controlled to move up and down in a predetermined manner, so that a fine sugar needle (substantially jewel-shaped, needle tip diameter 7 μm, needle length 600 μm, The needle bottom surface is substantially the same square shape as the top surface of the pedestal, and the substantially middle portion in the needle length direction is a substantially square having a side of 500 μm inscribed in a circle having a diameter of 707 μm. A pharmaceutical agent administration device having a single fine sugar needle was prepared (the outline of the outline is as shown in FIG. 10). Next, in order to conduct a skin insertion test on the pharmaceutical agent administration device, a fine saccharide needle was inserted into the skin in the same manner as in Example 11. As a result, it was possible to insert the skin in a painless state, and all the fine sugars were inserted into the skin. The needle could be left (ie, about 0.22 mg maltose and about 2.2 μg trichlormethiazide were administered simultaneously in the body). Further, 45 minutes after the completion of the intradermal insertion test, when the blood pressure of a subject whose average maximum blood pressure value is 180 Hg was measured, a blood pressure stabilizing effect appeared relatively well in a blood pressure range lower than 150 Hg, and the maximum The time to reach a dangerous area where the blood pressure value was 160 Hg or more was considerably reduced, and the effect of stabilizing and suppressing blood pressure by trichlormethiazide was confirmed.

  The functional agent administration device, the production method and the production apparatus of the present invention have various characteristic effects as described above, and are practically used in the beauty field, the medical field, and the like using nutrients and pharmaceutical agents due to these effects. it can. Moreover, the functional agent administration device, the production method and the production apparatus of the present invention can be mass-produced and can be used industrially.

  It is the schematic of the fine sugar needle | hook provided on the board | substrate by the conventional extending | stretching system.   It is the schematic of the board | substrate upper base (substantially cylindrical shape) in the functional agent administration device of this invention.   1 is a schematic view of a functional agent administration device having a substantially conical fine sugar needle of the present invention. FIG.   It is the schematic which shows the cross section of the functional agent administration device which integratedly manufactured the base and the board | substrate.   It is the schematic which shows the cross section of the functional agent administration device which manufactured the base and the board | substrate separately.   1 is a schematic view of a functional agent administration device having a bell-shaped fine sugar needle of the present invention.   It is the schematic of the functional agent administration device which has the jewel-shaped fine sugar needle | hook of this invention.   1 is a schematic view of a functional agent administration device having a substantially quadrangular pyramid-shaped fine sugar needle of the present invention. FIG.   1 is a schematic view of a functional agent administration device having a substantially sugar-shaped fine sugar needle of the present invention.   It is the schematic of the functional agent administration device which has a substantially jewel-shaped fine sugar needle of the present invention.   It is a schematic diagram which shows the state in the middle of preparation of the fine sugar needle by the fine sugar needle manufacturing apparatus based on the conventional enlargement system.   It is a schematic diagram which shows the state in the middle of preparation of the fine sugar needle | hook by the manufacturing apparatus of the functional agent administration device of this invention.   It is a schematic diagram which shows the production completion state of the fine carbohydrate needle | hook by the manufacturing apparatus of the functional agent administration device of this invention.

Explanation of symbols

DESCRIPTION OF SYMBOLS 1 Fine sugar needle by conventional stretching method 2 Substrate 3 Pedestal made of polysaccharide 4 Pedestal top surface 5 Pedestal bottom surface 6 Substrate made of polysaccharide 7 Substantially conical fine sugar needle 8 Pedestal and substrate manufactured integrally 9 Separation Produced pedestal 10 Separately manufactured substrate 11 Bell-shaped fine sugar needle 12 Jewel-shaped fine sugar needle 13 Substantially pyramid-shaped fine saccharide needle 14 Substantially bell-shaped fine saccharide needle 15 Substantially jewel-shaped Fine carbohydrate needle 16 Elevation control mechanism 17 of molten sugar material supply machine Molten sugar material supply machine 18 Nozzle 19 Molten sugar material 20 Substrate heater 21 Elevation control mechanism 22 of substrate attachment stage 23 Substrate attachment stage 23 Sugar heating container 24 Fine carbohydrate needle 25 during stretching of molten sugar material 25 Positioning control mechanism 26 by laser beam interference Reciprocating laser beam 27 Fine sugar needle by stretching molten sugar material

Claims (13)

  A plurality of pedestals made of a substantially cylindrical polysaccharide having a pedestal height of 10 μm to 2 mm, a pedestal top surface diameter of 30 μm to 1 mm, and a pedestal bottom surface diameter of 40 μm to 1.5 mm on the substrate made of polysaccharide. On the pedestal, a fine cone needle having a substantially conical or bell shape with a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface diameter of 30 μm to 1 mm in contact with the pedestal top surface is provided. A functional agent administration device having a provided structure.   A plurality of pedestals made of a substantially cylindrical polysaccharide having a pedestal height of 10 μm to 2 mm, a pedestal top surface diameter of 30 μm to 1 mm, and a pedestal bottom surface diameter of 40 μm to 1.5 mm on the substrate made of polysaccharide. Provided on the pedestal, the diameter of the needle tip is 0.5 μm to 20 μm, the needle length is 50 μm to 2 mm, the diameter of the needle bottom surface in contact with the pedestal upper surface is 30 μm to 1 mm, and the maximum diameter at the approximate middle in the needle length direction is 50 μm. A functional agent administration device having a structure in which a jewel-shaped fine sugar needle having a diameter of ˜1.5 mm is provided.   On a substrate made of a polysaccharide, a pedestal height of 10 μm to 2 mm, a pedestal top surface is inscribed or circumscribed in a circle having a diameter of 30 μm to 1 mm, and a pedestal bottom surface in contact with the substrate is inscribed in a circle having a diameter of 40 μm to 1.5 mm A plurality of pedestals made of a polysaccharide having a substantially polygonal column shape that is circumscribed are provided. On the pedestal, a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface have the same shape as the top surface of the pedestal. A functional agent administration device having a structure in which a fine sugar needle having a substantially polygonal pyramid shape or a bell shape is provided.   On a substrate made of a polysaccharide, a pedestal height of 10 μm to 2 mm, a pedestal top surface is inscribed or circumscribed in a circle having a diameter of 30 μm to 1 mm, and a pedestal bottom surface in contact with the substrate is inscribed in a circle having a diameter of 40 μm to 1.5 mm A plurality of pedestals made of a polysaccharide having a substantially polygonal column shape that circumscribes the pedestal, a needle tip diameter of 0.5 μm to 20 μm, a needle length of 50 μm to 2 mm, and a needle bottom surface having the same shape as the top surface of the pedestal, Administration of a functional agent, characterized in that a substantially saccharide-shaped fine saccharide needle having a substantially polygonal shape in which a substantially middle portion in the needle length direction is inscribed or circumscribed in a circle having a diameter of 50 μm to 1.5 mm is provided. device.   The functional agent administration device according to any one of claims 1 to 4, wherein the polysaccharide is pullulan or carboxymethylcellulose, and the sugar of the fine sugar needle is maltose.   5. The polysaccharide according to claim 1, wherein the polysaccharide is pullulan or carboxymethylcellulose, and the sugar of the fine sugar needle is a carbohydrate mixture containing maltose as a main component and glucose or trehalose as another component. The functional agent administration device according to claim 1.   To the carbohydrates of the fine sugar needle, vitamin A, vitamin B complex, vitamin C, vitamin D, vitamin E, vitamin K, glutamine, essential amino acid, non-essential amino acid, γ-aminobutyric acid, taurine, fatty acid, nucleic acid, The functional agent administration device according to claim 5 or 6, further comprising one or more nutrients selected from adrenaline.   Analyzing drugs, anti-inflammatory drugs, antipyretic analgesic / anti-inflammatory drugs, antifungal drugs, antibacterial drugs, antiviral drugs, cardiotonic drugs, thrombolytic drugs, hemostatic drugs, diuretics, antihypertensive drugs, anesthesia 1 pharmaceutical agent selected from an agent, a sedative, a sleeping pill, an anticonvulsant, an anxiolytic, a sickness-stopper, a tranquilizer, an antidepressant, a sleep sedative, and an antiprotozoal The functional agent administration device according to claim 5 or 6.   After forming a plurality of pedestals made of the polysaccharide by mold molding on the substrate made of the polysaccharide, the pedestal is placed on a stage along a horizontal plane having an elevation control mechanism so that the pedestal points in a vertically downward direction. The pedestal upper surface is brought into contact with the upper surface of the molten saccharide in the saccharide heating container whose temperature is controlled at 90 ° C. to 120 ° C. in a stationary state, and then the stage is moved up and down to raise the pedestal upper surface. The method for producing a functional agent administration device according to any one of claims 1 to 8, wherein the fine saccharide needle is molded into the same.   After forming a plurality of pedestals made of the polysaccharide by mold molding on the substrate made of the polysaccharide, the pedestal is placed on a stage along a horizontal plane having an elevation control mechanism so that the pedestal points in a vertically downward direction. The pedestal upper surface is brought into contact with the upper surface of the molten saccharide in the saccharide heating container whose temperature is controlled at 90 ° C. to 120 ° C. in a stationary state, and then the stage is moved up and down to raise the pedestal upper surface. The functional agent administration device according to any one of claims 1 to 8, wherein the fine agent needle is molded into a functional agent administration device manufacturing method.   The fine sugar needle is placed on the upper surface of the pedestal with a high accuracy by a control method that finely divides the vertical movement distance of the stage into a digital type and finely adjusts the vertical movement speed by arbitrarily changing the vertical movement distance. The method for producing a functional agent administration device according to claim 9, wherein the functional agent administration device is formed into a shape.   10. The method of manufacturing a functional agent administration device according to claim 9, wherein the vertical movement distance of the stage is finely divided digitally, and the vertical movement speed is finely adjusted by arbitrarily changing the vertical movement distance. The functional agent administration device according to claim 1, wherein the fine sugar needle is formed with high accuracy on the upper surface of the pedestal by the method for producing a functional agent administration device.   The apparatus for manufacturing a functional agent administration device includes a sugar heating container having a temperature control mechanism of 90 ° C. to 120 ° C., and a lift control mechanism capable of attaching the substrate so that the pedestal points in a vertically downward direction. 9. The stage along a horizontal plane, and further comprising the stage having an alignment control mechanism for arbitrarily positioning a distance between the upper surface of the base and the upper surface of the molten carbohydrate. An apparatus for manufacturing a functional agent administration device according to any one of the above.

Images